The stock of Revolution Medicines Inc (RVMD) has seen a -2.11% decrease in the past week, with a 0.00% drop in the past month, and a 3.05% flourish in the past quarter. The volatility ratio for the week is 1.84%, and the volatility levels for the past 30 days are at 2.76% for RVMD. The simple moving average for the past 20 days is 0.16% for RVMD’s stock, with a -8.10% simple moving average for the past 200 days.
Is It Worth Investing in Revolution Medicines Inc (NASDAQ: RVMD) Right Now?
Additionally, the 36-month beta value for RVMD is 1.10. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for RVMD is 161.93M and currently, short sellers hold a 11.34% ratio of that float. The average trading volume of RVMD on June 20, 2025 was 1.85M shares.
RVMD) stock’s latest price update
Revolution Medicines Inc (NASDAQ: RVMD) has experienced a rise in its stock price by 2.02 compared to its previous closing price of 39.14. However, the company has seen a fall of -2.11% in its stock price over the last five trading days. seekingalpha.com reported 2025-06-19 that Revolution Medicines is advancing a groundbreaking pan-RAS inhibitor pipeline, targeting historically undruggable mutations in tough cancers like pancreatic and lung. Early clinical data for daraxonrasib and zoldonrasib show strong efficacy and tolerability, sparking excitement among oncologists and analysts alike. Despite a robust cash position, RVMD’s high burn rate and lofty valuation increase risk and sensitivity to setbacks, making entry timing challenging.
Analysts’ Opinion of RVMD
Many brokerage firms have already submitted their reports for RVMD stocks, with Needham repeating the rating for RVMD by listing it as a “Buy.” The predicted price for RVMD in the upcoming period, according to Needham is $62 based on the research report published on July 16, 2024 of the previous year 2024.
Barclays, on the other hand, stated in their research note that they expect to see RVMD reach a price target of $52. The rating they have provided for RVMD stocks is “Overweight” according to the report published on July 12th, 2024.
Jefferies gave a rating of “Buy” to RVMD, setting the target price at $63 in the report published on July 08th of the previous year.
RVMD Trading at 2.45% from the 50-Day Moving Average
After a stumble in the market that brought RVMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.01% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RVMD starting from Horn Margaret A, who sale 3,510 shares at the price of $39.83 back on Jun 16 ’25. After this action, Horn Margaret A now owns 150,675 shares of Revolution Medicines Inc, valued at $139,803 using the latest closing price.
GOLDSMITH MARK A, the of Revolution Medicines Inc, sale 13,496 shares at $39.83 during a trade that took place back on Jun 16 ’25, which means that GOLDSMITH MARK A is holding 428,720 shares at $537,546 based on the most recent closing price.
Stock Fundamentals for RVMD
Current profitability levels for the company are sitting at:
- -3.02 for the present operating margin
- 0.45 for the gross margin
The net margin for Revolution Medicines Inc stands at -2.67. The total capital return value is set at -0.36. Equity return is now at value -36.68, with -32.64 for asset returns.
Based on Revolution Medicines Inc (RVMD), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -4.4.
Currently, EBITDA for the company is -589.02 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 27.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.46.
Conclusion
In conclusion, Revolution Medicines Inc (RVMD) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
